HBM Holdings(02142.HK): IND Application of HBM7575 for Asthma Treatment Approved by NMPA
NewTimeSpace News: On 15 July 2026, HBM Holdings(02142.HK) issued an announcement that the Investigational New Drug application for HBM7575 (also known as SKB575), a long-acting bispecific antibody targeting TSLP and an undisclosed target, has obtained approval from the NMPA for asthma treatment.
As stated in the announcement, this bispecific antibody is co-developed by the Company and Kelun-Biotech. It exerts synergistic effects by blocking the TSLP signaling pathway and another undisclosed target, and is expected to achieve broader control over inflammation.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HBM Holdings (02142.HK): Included as a Constituent Stock of Hang Seng Composite Index
- HBM Holdings(02142.HK): Strategic Cooperation Established with Sinopharm Group
- HBM HOLDINGS-B (02142.HK): IND application of HBM7004 for advanced solid tumors approved by NMPA
- HBM HOLDINGS-B (02142.HK): Expected Profit of USD62 Million–USD67 Million for H1 2026; Revenue Stood at Approximately USD101 Million in Corresponding Period Last Year
